Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11

References

• DesjeuxPLeishmaniasis: current situation and new perspectivesComp Immunol Microbiol Infect Dis200427530531815225981
   PubMed Web of Science ®Google Scholar
• MarsdenPDMucosal leishmaniasis (“espundia” Escomel, 1911)Trans R Soc Trop Med Hyg19868068598763037735
   PubMed Web of Science ®Google Scholar
• BittencourtABarral-NettoMLeishmaniasis82nd edDoerrWSeifertGTropical PathologyBerlinSpringer1995
   Google Scholar
• AlvarJYactayoSBernCLeishmaniasis and povertyTrends Parasitol2006221255255717023215
   PubMed Web of Science ®Google Scholar
• ScottPNatovitzPCoffmanRLPearceESherAImmunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigensJ Exp Med19881685167516842903212
   PubMed Web of Science ®Google Scholar
• LiewFYMillottSParkinsonCPalmerRMMoncadaSMacrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginineJ Immunol199014412479447972351828
   PubMed Web of Science ®Google Scholar
• de OliveiraCINascimentoIPBarralASotoMBarral-NettoMChallenges and perspectives in vaccination against leishmaniasisParasitol Int200958431932419698801
   PubMed Web of Science ®Google Scholar
• OkworIUzonnaJVaccines and vaccination strategies against human cutaneous leishmaniasisHum Vaccin20095529130119221514
   PubMed Web of Science ®Google Scholar
• RamshawIARamsayAJThe prime-boost strategy: exciting prospects for improved vaccinationImmunol Today200021416316510740236
   PubMedGoogle Scholar
• RamiroMJZarateJJHankeTProtection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACKVaccine20032119–202474248412744881
   PubMed Web of Science ®Google Scholar
• DondjiBPerez-JimenezEGoldsmith-PestanaKEstebanMMcMahon-PrattDHeterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasisInfect Immun20057385286528916041057
   PubMed Web of Science ®Google Scholar
• RafatiSZahedifardFAzariMKTaslimiYTaheriTLeishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c miceExp Parasitol2008118339340118093586
   PubMed Web of Science ®Google Scholar
• GonzaloRMdel RealGRodriguezJRA heterologous prime- boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasisVaccine2002207–81226123111803085
   PubMed Web of Science ®Google Scholar
• TapiaEPerez-JimenezELopez-FuertesLGonzaloRGherardiMMEstebanMThe combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACKMicrobes Infect200352738412650765
   PubMed Web of Science ®Google Scholar
• AbdianNGholamiEZahedifardFSafaeeNRafatiSEvaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasisExp Parasitol2011127362763621187087
   PubMed Web of Science ®Google Scholar
• O’HaganDTRahmanDMcGeeJPBiodegradable microparticles as controlled release antigen delivery systemsImmunology19917322392422071168
   PubMed Web of Science ®Google Scholar
• CarcabosoAMHernandezRMIgartuaMRosasJEPatarroyoMEPedrazJLPotent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticlesVaccine20042211–121423143215063565
   PubMed Web of Science ®Google Scholar
• HamdySMolaviOMaZCo-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunityVaccine200826395046505718680779
   PubMed Web of Science ®Google Scholar
• ChongCSWCaoMWongWWEnhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine deliveryJ Control Release20051021859915653136
   PubMed Web of Science ®Google Scholar
• DoroudDZahedifardFVatanaraADelivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infectionJ Control Release2011153215416221530597
   PubMed Web of Science ®Google Scholar
• TafaghodiMKhamesipourAJaafariMRImmunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODNParasitol Res201110851265127321125294
   PubMed Web of Science ®Google Scholar
• JardimAFunkVCaprioliRMOlafsonRWIsolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoproteinBiochem J.1995305Pt 13073137826346
   PubMed Web of Science ®Google Scholar
• JensenATGasimSIsmailAHumoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11Scand J Immunol19984811031099714418
   PubMed Web of Science ®Google Scholar
• ThomasMCGarcia-PerezJLAlonsoCLopezMCMolecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeleton-associated protein regulated at the translational levelDNA Cell Biol2000191475710668791
   PubMed Web of Science ®Google Scholar
• BasuRBhaumikSBasuJMNaskarKDeTRoySKinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasisJ Immunol2005174117160717115905560
   PubMed Web of Science ®Google Scholar
• BhaumikSBasuRSenSNaskarKRoySKMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. majorVaccine20092791306131619162111
   PubMed Web of Science ®Google Scholar
• CostaCHPetersNCMaruyamaSRde BritoECJrSantosIKVaccines for the leishmaniases: proposals for a research agendaPLoS Negl Trop Dis201153e94321468307
   PubMed Web of Science ®Google Scholar
• FuertesMAPerezJMSotoMLopezMCAlonsoCCalcium-induced conformational changes in Leishmania infantum kinetoplastid membrane protein-11J Biol Inorg Chem20016110711711191218
   PubMed Web of Science ®Google Scholar
• FuertesMABerberichCLozanoRMGimenez-GallegoGAlonsoCFolding stability of the kinetoplastid membrane protein-11 (KMP-11) from Leishmania infantumEur J Biochem1999260255956710095795
   PubMedGoogle Scholar
• del BarrioGGNovoFJIracheJMLoading of plasmid DNA into PLGA microparticles using TROMS (total recirculation one-machine system): evaluation of its integrity and controlled release propertiesJ Control Release200386112313012490378
   PubMed Web of Science ®Google Scholar
• IborraSCarrionJAndersonCAlonsoCSacksDSotoMVaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c miceInfect Immun20057395842585216113303
   PubMed Web of Science ®Google Scholar
• de MouraTRNovaisFOOliveiraFToward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensisInfect Immun20057395827583416113301
   PubMed Web of Science ®Google Scholar
• de MouraTROliveiraFRodriguesGCImmunity to Lutzomyia intermedia saliva modulates the inflammatory environment induced by Leishmania braziliensisPLoS Negl Trop Dis201046e71220559550
   PubMed Web of Science ®Google Scholar
• de MouraTROliveiraFNovaisFOEnhanced Leishmania braziliensis infection following pre-exposure to sandfly salivaPLoS Negl Trop Dis200712e8418060088
   PubMed Web of Science ®Google Scholar
• LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta c(t)) methodMethods200125440240811846609
   PubMed Web of Science ®Google Scholar
• KedmiRBen-ArieNPeerDThe systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activationBiomaterials201031266867687520541799
   PubMed Web of Science ®Google Scholar
• KrugARothenfusserSHornungVIdentification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cellsEur J Immunol20013172154216311449369
   PubMed Web of Science ®Google Scholar
• de CarvalhoLPSotoMJeronimoSCharacterization of the immune response to Leishmania infantum recombinant antigensMicrobes Infect20035171212593967
   PubMed Web of Science ®Google Scholar
• CarvalhoLPPassosSDutraWOEffect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patientsScand J Immunol200561433734215853916
   PubMed Web of Science ®Google Scholar
• BelkaidYPiccirilloCAMendezSShevachEMSacksDLCD4+ CD25+ regulatory T cells control Leishmania major persistence and immunityNature2002420691550250712466842
   PubMed Web of Science ®Google Scholar
• SinghMBrionesMOttGO’HaganDCationic microparticles: a potent delivery system for DNA vaccinesProc Natl Acad Sci U S A200097281181610639162
   PubMed Web of Science ®Google Scholar
• DoroudDZahedifardFVatanaraANajafabadiARRafatiSCysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 miceParasite Immunol201133633534821410716
   PubMed Web of Science ®Google Scholar
• Rice-FichtACArenas-GamboaAMKahl-McDonaghMMFichtTAPolymeric particles in vaccine deliveryCurr Opin Microbiol201013110611220079678
   PubMed Web of Science ®Google Scholar
• StorniTKundigTMSentiGJohansenPImmunity in response to particulate antigen-delivery systemsAdv Drug Deliv Rev200557333335515560945
   PubMed Web of Science ®Google Scholar
• SalayGDortaMLSantosNMTesting of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New WorldClin Vaccine Immunol20071491173118117626159
   PubMedGoogle Scholar
• TonuiWKTitusRGCross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c miceAm J Trop Med Hyg200776357958417360887
   PubMed Web of Science ®Google Scholar